AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Health Equity
Health inequities persist in the U.S. and globally, especially in low- and middle-income countries, where limited access to care leads to poorer outcomes. This section explores cancer through the lens of equity, highlighting emerging research, tools, and technologies working to close the gap and advance more just, inclusive cancer care.
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
ASCO23 – LUNAR Study Summary
By Editorial Team
**Author:** Lei Deng, MD [Roswell Park Comprehensive Cancer Center](https://www.roswellpark.org/) _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 [**LBA9005**](https://meetings.asco.org/ab...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
A Summary of the DACOTA Trial
By Editorial Team
By Dr. Chepsy Philip [Believer's Church Medical College Hospital](https://www.bcmch.org/) Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of C...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
AEGEAN trial: A phase 3 study of Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab versus Neoadjuvant Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer
By Editorial Team
By Dr. Dipesh Uprety [Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the stan...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
2022 Updates in Lung Cancer Treatment
By Editorial Team
2022 Updates in Lung Cancer Treatment
By Editorial Team
2022 Updates in Lung Cancer Treatment
By Editorial Team
2023 Summit on Cancer Health Disparities (SCHD)
By Editorial Team
2023 Summit on Cancer Health Disparities (SCHD)
By Editorial Team
2023 Summit on Cancer Health Disparities (SCHD)
By Editorial Team
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Binaytara Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Binaytara Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia
By Binaytara Team
Dr. Aditi Sharma of [Barbara Ann Karmanos Cancer Institute](https://www.karmanos.org/karmanos/karmanos-home) & Dr. Abhishek Mangaonkar of [Mayo Clinic](https://www.mayoclinic.org/) In the phase III ...
Announcing Binaytara's 2023 Summit on Cancer Health Disparities (SCHD23)
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Announcing Binaytara's 2023 Summit on Cancer Health Disparities (SCHD23)
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Announcing Binaytara's 2023 Summit on Cancer Health Disparities (SCHD23)
By Editorial Team
The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 ------------------------------------------------------------------------------ We invite you to attend the 2023 Summit o...
Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)
By Editorial Team
Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities --------------------------------------------------------------------------- The Binaytara Foundation has named Dr. Umang Sw...
Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)
By Editorial Team
Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities --------------------------------------------------------------------------- The Binaytara Foundation has named Dr. Umang Sw...
Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)
By Editorial Team
Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities --------------------------------------------------------------------------- The Binaytara Foundation has named Dr. Umang Sw...
A recap from our 2nd Annual Charity Gala Dinner
By Editorial Team
Binaytara’s Second Annual Gala Dinner was held on July 24, 2021, at the Crowne-Plaza Downtown Seattle and over 100 guests came out to support the organization’s efforts to eliminate global cancer care...
A recap from our 2nd Annual Charity Gala Dinner
By Editorial Team
Binaytara’s Second Annual Gala Dinner was held on July 24, 2021, at the Crowne-Plaza Downtown Seattle and over 100 guests came out to support the organization’s efforts to eliminate global cancer care...
A recap from our 2nd Annual Charity Gala Dinner
By Editorial Team
Binaytara’s Second Annual Gala Dinner was held on July 24, 2021, at the Crowne-Plaza Downtown Seattle and over 100 guests came out to support the organization’s efforts to eliminate global cancer care...